Tag: dupilumab Dupixent

All

Dupilumab Lessens Disease in COPD Patients

The monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD, according to investigators.

NIH to Trial Dupilumab for Asthma
NIH Launches Monoclonal Antibody Trial to Treat Asthma in Urban Youth
Functional Respiratory Imaging to Assess Dupilumab
Dupilumab Gets Expanded Approval for Moderate-to-severe Asthma in Children Age 6-11
Dupilumab May Improve Lung Function in Children Age 6-11 with Uncontrolled, Moderate to Severe Asthma
Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11
FDA to Review Expanded Application of Dupixent for Childhood Asthma

All

Self-administered Dupixent Pen Approved for Asthma, CRSwNP

FDA approved a 300 mg single-dose pre-filled pen for Dupixent (dupilumab) to treat atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).

Dupixent Effective for Chronic Rhinosinusitus with Nasal Polyps
Dupilumab Improves QoL in Uncontrolled Asthma and Allergic Rhinitis

Tag: dupilumab Dupixent

All

Dupilumab Lessens Disease in COPD Patients

NIH to Trial Dupilumab for Asthma

NIH Launches Monoclonal Antibody Trial to Treat Asthma in Urban Youth

Functional Respiratory Imaging to Assess Dupilumab

Dupilumab Gets Expanded Approval for Moderate-to-severe Asthma in Children Age 6-11

Dupilumab May Improve Lung Function in Children Age 6-11 with Uncontrolled, Moderate to Severe Asthma

Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11

FDA to Review Expanded Application of Dupixent for Childhood Asthma

All

Self-administered Dupixent Pen Approved for Asthma, CRSwNP

Dupixent Effective for Chronic Rhinosinusitus with Nasal Polyps

Dupilumab Improves QoL in Uncontrolled Asthma and Allergic Rhinitis

All

Sorry, No Posts Found

Sorry, No Posts Found